Zhang, Mingxiang
National Taiwan University Hospital
2 papers on CoChatORCID 0000-0003-3084-0775
Most cited papers
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling
Zhang, Y., Li, R., Meng, Y., Li, S., Donelan, W., Zhao, Y., Qi, L., Zhang, M., Wang, X., Cui, T., et al. (2014) · Diabetes
Adipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic Diseases
Cited by 733
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free